Analysis of TGFB1 in European and Japanese Moyamoya disease patients

European Journal of Medical Genetics

Volumn 55, Issue 10, 2012, Pages 531-534

  Liu, Chao ^a,b   Roder, Constantin ^a   Schulte, Claudia ^c   Kasuya, Hidetoshi ^d   Akagawa, Hiroyuki ^e   Nishizawa, Tsutomu ^f   Yoneyama, Taku ^d   Okada, Yoshikazu ^d   Khan, Nadia ^g   Tatagiba, Marcos ^a   Berg, Daniela ^a   Krischek, Boris ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Genetics; Growth factors; Moyamoya disease; Single nucleotide polymorphism; TGFB1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EUROPE; EXON; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MOYAMOYA DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; EUROPE; EXONS; FEMALE; HUMANS; INFANT; JAPAN; MALE; MIDDLE AGED; MOYAMOYA DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84866382265     PISSN: 17697212     EISSN: 18780849     Source Type: Journal    
DOI: 10.1016/j.ejmg.2012.05.002     Document Type: Article

References (16)

1. Achrol A.S., Guzman R., Lee M., Steinberg G.K. Pathophysiology and genetic factors in Moyamoya disease. Neurosurg. Focus 2009, 26:E4.
2. Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis (Moyamoya disease). Clin. Neurol. Neurosurg. 1997, 99(Suppl 2):S238-S240.
3. Guo D.-C., Papke C.L., Tran-Fadulu V., Regalado E.S., Avidan N., Johnson R.J., Kim D.H., Pannu H., Willing M.C., Sparks E., Pyeritz R.E., Singh M.N., Dalman R.L., Grotta J.C., Marian A.J., Boerwinkle E.A., Frazier L.Q., LeMaire S.A., Coselli J.S., Estrera A.L., Safi H.J., Veeraraghavan S., Muzny D.M., Wheeler D.A., Willerson J.T., Yu R.K., Shete S.S., Scherer S.E., Raman C.S., Buja L.M., Milewicz D.M. Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am. J. Hum. Genet. 2009, 84:617-627.
4. Hervé D., Touraine P., Verloes A., Miskinyte S., Krivosic V., Logeart D., Alili N., Laredo J.D., Gaudric A., Houdart E., Metzger J.P., Tournier-Lasserve E., Woimant F. A hereditary Moyamoya syndrome with multisystemic manifestations. Neurology 2010, 75:259-264.
5. Hojo M., Hoshimaru M., Miyamoto S., Taki W., Nagata I., Asahi M., Matsuura N., Ishizaki R., Kikuchi H., Hashimoto N. Role of transforming growth factor-ß1 in the pathogenesis of Moyamoya disease. J. Neurosurg. 1998, 89:623-629.
6. Janssens K., ten Dijke P., Janssens S., van Hul W. Transforming growth factor-ß1 to the bone. Endocr. Rev. 2005, 26:743-774.
7. Koch W., Hoppmann P., Mueller J.C., Schomig A., Kastrati A. Association of transforming growth factor-ß1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1114-1119.
8. Kraemer M., Heienbrok W., Berlit P. Moyamoya disease in Europeans. Stroke 2008, 39:3193-3200.
9. Krischek B., Kasuya H., Khan N., Tatagiba M., Roder C., Kraemer M. Genetic and clinical characteristics of Moyamoya disease in Europeans. Trends Neurovasc. Surg. Acta Neurochir. 2011, 112(Suppl):31-34.
10. Milewicz D.M., Kwartler C.S., Papke C.L., Regalado E.S., Cao J., Reid A.J. Genetic variants promoting smooth muscle cell proliferation can result in diffuse and diverse vascular diseases: evidence for a hyperplastic vasculomyopathy. Genet. Med. 2010, 12:196-203.
11. Milewicz D.M., Østergaard J.R., Ala-Kokko L.M., Khan N., Grange D.K., Mendoza-Londono R., Bradley T.J., Olney A.H., Adès L., Maher J.F., Guo D., Buja L.M., Kim D., Hyland J.C., Regalado E.S. De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am. J. Med. Genet. 2010, 152A:2437-2443.
12. Mohren S., Weiskirchen R. Non-synonymous gene polymorphisms in the secretory signal peptide of human TGF-ß1 affect cellular synthesis but not secretion of TGF-ß1. Biochem. Biophys. Res. Commun. 2009, 379:1015-1020.
13. Roder C., Nayak N.R., Khan N., Tatagiba M., Inoue I., Krischek B. Genetics of Moyamoya disease. J. Hum. Gen. 2010, 55:711-716.
14. Roder C., Peters V., Kasuya H., Nishizawa T., Takehara Y., Berg D., Schulte C., Khan N., Tatagiba M., Krischek B. Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients. Acta Neurochir. 2010, 152:2153-2160.
15. Scott R.M., Smith E.R. Moyamoya disease and Moyamoya syndrome. N. Engl. J. Med. 2009, 360:1226-1237.
16. Yoshimoto T., Houkin K., Takahashi A., Abe H. Angiogenic factors in Moyamoya disease. Stroke 1996, 27:2160-2165.